Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts
Por um escritor misterioso
Descrição
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only one of its questions is specific to axial symptoms. Alternatively, the Ankylosing Spondylitis Disease Activity Score (ASDAS) excludes assessment of enthesitis, gives less weight to peripheral activity and is considered […]
PDF) Axial involvement in psoriatic arthritis: An update for rheumatologists
POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY
Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial - ACR Meeting Abstracts
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA - ACR Meeting Abstracts
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA - ACR Meeting Abstracts
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study - ACR Meeting Abstracts
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial, Trials
Canadian Rheumatology Association Meeting Quebec City Convention Centre Quebec City, Quebec, Canada February 8–11, 2023
Treat to Target in Spondyloarthritis: Myth or Reality? - European Medical Journal
Plenary Presentations - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library
PDF) The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
de
por adulto (o preço varia de acordo com o tamanho do grupo)
